A clinical summary of GLP-1 outcomes for women with weight-loss resistance: what the STEP trials found

For many women, the experience is the same: years of genuine effort, careful eating, consistent movement, and a scale that does not respond. The explanation from most doctors is vague. The STEP research program, the most extensive weight-loss trial ever conducted, gave a specific one: the brain's satiety feedback circuit had broken down.

What the research found

The Study

STEP Program, Semaglutide Treatment Effect in People with Obesity

Randomised, double-blind, placebo-controlled. Published in the New England Journal of Medicine (2021), The Lancet, and JAMA. 45,000+ participants, 68 countries. Primary group: women aged 35 to 60 with documented weight-loss resistance.

The study found the problem was neurological. In women who had experienced pregnancy, age-related estrogen decline, or prolonged stress, the hypothalamus had lost sensitivity to the body's fullness signals. The "stop eating" message was arriving too late or being suppressed. The result: persistent hunger, compulsive food thoughts, and cravings independent of caloric intake.

"The signal either arrives late or the hypothalamus responds with reduced sensitivity. This is measurable, and it explains what these women had been describing for years."

STEP Trial Summary, New England Journal of Medicine, 2021

What they were prescribed

Medication	Average loss	20%+ outcomes	Method
Semaglutide	-15.3%	22% of group	Weekly injection or oral
Tirzepatide, strongest results	-22.5%	32% of group	Weekly injection
Diet and exercise only	-2.4%	2% of group

The protocol that produced the best results

The clinical picture

Assessment

Consistent effort with no lasting result for years points to biology, not behaviour. GLP-1 medications are the only intervention shown to address the satiety signalling mechanism directly. A 160-pound woman averaged 24 pounds lost at six months. These are averages across all 45,000 participants.

How the cost changed

Brand-name GLP-1 medications cost over $1,000 a month without insurance. TrimRx provides clinician-prescribed semaglutide and tirzepatide through FDA-registered compounding pharmacies. Same active compounds. Pharmaceutical standards. Doctor-supervised. Shipped to your door.

Brand-name retail

$1,300+

Per month, no insurance

vs

TrimRx programme

OK

Clinician-prescribed, FDA-reg. pharmacy

Same active compounds. Pharmaceutical standards. Doctor-supervised. Free delivery. The medication is the same. The price is different.

Free Assessment

Start the free TrimRx eligibility check

If your profile matches the study, prior diet resistance, hormonal shifts, biological hunger, you likely qualify. A licensed clinician reviews every submission.

Same active compounds

Clinician-prescribed

FDA-registered pharmacy

Free delivery

No insurance needed

Cancel anytime

Start free eligibility check

No payment at assessment · Physician-reviewed · US residents only

Disclosure: sponsored content in partnership with TrimRx. Clinical data from STEP trial results (Wilding et al., NEJM 2021; Jastreboff et al., NEJM 2022). Average outcomes do not guarantee individual results. Compounded medications are not FDA-approved as finished drug products. Programme requires physician oversight. Individual results vary.

Registered Company

WAFFLE ADVERTISING LTD

Registered address: 85 Great Portland Street, London, W1W 7LT, United Kingdom